Myxoma virus induces apoptosis in cultured feline carcinoma cells

Research in Veterinary Science

Volumn 93, Issue 2, 2012, Pages 1036-1038

  MacNeill, A L ^a   Moldenhauer, T ^a   Doty, R ^a   Mann, T ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

Feline cancer; Feline carcinoma; Myxoma virus; Viral oncolysis

Indexed keywords

ONCOLYTIC MYXOMA VIRUS; ONCOLYTIC VIRUS; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CARCINOMA CELL; CAT; CAT DISEASE; CONTROLLED STUDY; DRUG EFFICACY; FELINE SQUAMOUS CELL CARCINOMA; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; MYXOMA VIRUS; NONHUMAN; ONCOLYTIC VIROTHERAPY; POXVIRUS INFECTION; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; VIRUS PARTICLE; VIRUS REPLICATION;

ANIMALS; APOPTOSIS; CARCINOMA; CAT DISEASES; CATS; CELL CULTURE TECHNIQUES; FEMALE; MAMMARY NEOPLASMS, ANIMAL; MYXOMA VIRUS;

FELIDAE; MYXOMA VIRUS; ORYCTOLAGUS CUNICULUS;

EID: 84863091875     PISSN: 00345288     EISSN: 15322661     Source Type: Journal    
DOI: 10.1016/j.rvsc.2011.10.016     Document Type: Article

References (20)

1. Bull L.B., Dickinson C.G. The specificity of the virus of rabbit myxomatosis. Journal of the Council of Scientific and Industrial Research 1937, 10:291-294.
2. Fenner F., Woodroffe G.M. The Pathogenesis of Infectious Myxomatosis: The Mechanism of Infection and the Immunological Response in the European Rabbit (Oryctolagus cuniculus). British Journal of Experimental Pathology 1953, 34:400-411.
3. Gorski J., Mizak B., Chrobocinska M. Control of rabbit myxomatosis in Poland. Revue Scientifique et Technique 1994, 13:869-879.
4. Jourdier T.M., Moste C., Bonnet M.C., Delisle F., Tafani J.P., Devauchelle P., Tartaglia J., Moingeon P. Local immunotherapy of spontaneous feline fibrosarcomas using recombinant poxviruses expressing interleukin 2 (IL2). Gene Therapy 2003, 10:2126-2132.
5. Liu J., Wennier S., Reinhard M., Roy E., MacNeill A., McFadden G. Myxoma virus expressing interleukin-15 fails to cause lethal myxomatosis in European rabbits. Journal of Virology 2009, 83:5933-5938.
6. Lun X., Yang W., Alain T., Shi Z.Q., Muzik H., Barrett J.W., McFadden G., Bell J., Hamilton M.G., Senger D.L., Forsyth P.A. Myxoma virus is a novel oncolytic virus with significant antitumor activity against experimental human gliomas. Cancer Research 2005, 65:9982-9990.
7. Lun X.Q., Zhou H., Alain T., Sun B., Wang L., Barrett J.W., Stanford M.M., McFadden G., Bell J., Senger D.L., Forsyth P.A. Targeting human medulloblastoma: oncolytic virotherapy with myxoma virus is enhanced by rapamycin. Cancer Research 2007, 67:8818-8827.
8. Lun X., Alain T., Zemp F.J., Zhou H., Rahman M.M., Hamilton M.G., McFadden G., Bell J., Senger D.L., Forsyth P.A. Myxoma virus virotherapy for glioma in immunocompetent animal models: optimizing administration routes and synergy with rapamycin. Cancer Research 2010, 70:598-608.
9. MacNeill A.L., Turner P.C., Moyer R.W. Mutation of the Myxoma virus SERP2 P1-site to prevent proteinase inhibition causes apoptosis in cultured RK-13 cells and attenuates disease in rabbits, but mutation to alter specificity causes apoptosis without reducing virulence. Virology 2006, 356:12-22.
10. Maurer D.M., Harrington B., Lane J.M. Smallpox vaccine: Contraindications, administration, and adverse reactions. American Family Physician 2003, 68:889-896.
11. McCabe V.J., Tarpey I., Spibey N. Vaccination of cats with an attenuated recombinant myxoma virus expressing feline calicivirus capsid protein. Vaccine 2002, 20:2454-2462.
12. McCabe V.J., Spibey N. Potential for broad-spectrum protection against feline calicivirus using an attenuated myxoma virus expressing a chimeric FCV capsid protein. Vaccine 2005, 23:5380-5388.
13. Parato K.A., Senger D., Forsyth P.A., Bell J.C. Recent progress in the battle between oncolytic viruses and tumours. Nature Reviews Cancer 2005, 5:965-976.
14. Puhlmann M., Brown C.K., Gnant M., Huang J., Libutti S.K., Alexander H.R., Bartlett D.L. Vaccinia as a vector for tumor-directed gene therapy: Biodistribution of a thymidine kinase-deleted mutant. Cancer Gene Therapy 2000, 7:66-73.
15. Schreiber M., Sedger L., McFadden G. Distinct domains of M-T2, the myxoma virus tumor necrosis factor (TNF) receptor homolog, mediate extracellular TNF binding and intracellular apoptosis inhibition. Journal of Virology 1997, 71:2171-2181.
16. Spaner D.E., Astsaturov I., Vogel T., Petrella T., Elias I., Burdett-Radoux S., Verma S., Iscoe N., Hamilton P., Berinstein N.L. Enhanced viral and tumor immunity with intranodal injection of canary pox viruses expressing the melanoma antigen, gp100. Cancer 2006, 106:890-899.
17. Stanford M.M., Shaban M., Barrett J.W., Werden S.J., Gilbert P.A., Bondy-Denomy J., Mackenzie L., Graham K.C., Chambers A.F., McFadden G. Myxoma virus oncolysis of primary and metastatic B16F10 mouse tumors in vivo. Molecular Therapy 2008, 16:52-59.
18. Vanderplasschen A., Pastoret P.P. The uses of poxviruses as vectors. Current Gene Therapy 2003, 3:583-595.
19. Wang G., Barrett J.W., Nazarian S.H., Everett H., Gao X., Bleackley C., Colwill K., Moran M.F., McFadden G. Myxoma virus M11L prevents apoptosis through constitutive interaction with Bak. Journal of Virology 2004, 78:7097-7111.
20. Wang G., Barrett J.W., Stanford M., Werden S.J., Johnston J.B., Gao X., Sun M., Cheng J.Q., McFadden G. Infection of human cancer cells with myxoma virus requires Akt activation via interaction with a viral ankyrin-repeat host range factor. Proceedings of the National Academy of Sciences of the U S A 2006, 103:4640-4645.